Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 6.8%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 14,200 shares, an increase of 6.8% from the March 15th total of 13,300 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 18,300 shares, the short-interest ratio is currently 0.8 days.

Armata Pharmaceuticals Stock Down 0.6 %

ARMP opened at $3.23 on Tuesday. Armata Pharmaceuticals has a twelve month low of $1.07 and a twelve month high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.68 million. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. On average, sell-side analysts expect that Armata Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a report on Friday, March 22nd.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Armata Pharmaceuticals by 59.5% during the 4th quarter. Vanguard Group Inc. now owns 145,078 shares of the company’s stock worth $470,000 after acquiring an additional 54,109 shares in the last quarter. Jane Street Group LLC acquired a new position in Armata Pharmaceuticals during the 4th quarter worth $25,000. Renaissance Technologies LLC lifted its position in shares of Armata Pharmaceuticals by 5.6% in the 4th quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock worth $91,000 after buying an additional 3,900 shares during the last quarter. HRT Financial LP bought a new position in shares of Armata Pharmaceuticals in the 4th quarter worth about $52,000. Finally, Northern Trust Corp bought a new position in shares of Armata Pharmaceuticals in the 1st quarter worth about $95,000. 3.57% of the stock is owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.